Unknown

Dataset Information

0

PARP Inhibitors Combined with Abiraterone Overcome Resistance in Metastatic Castration-Resistant Prostate Cancer Independently of Androgen Receptor

ABSTRACT:

SUBMITTER: Mallah H 

PROVIDER: S-EPMC12939155 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer.
| S-EPMC3778906 | biostudies-literature
Unknown Abiraterone in the treatment of metastatic castration-resistant prostate cancer.
| S-EPMC3912049 | biostudies-literature
Unknown Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
| S-EPMC10431499 | biostudies-literature
Unknown Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer.
| S-EPMC11329885 | biostudies-literature
Unknown A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.
| S-EPMC5315609 | biostudies-literature
Unknown Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer.
| S-EPMC6499126 | biostudies-literature
Unknown A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer.
| S-EPMC7350510 | biostudies-literature
Unknown Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer.
| S-EPMC4257741 | biostudies-literature
Unknown <i>TP53</i> Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.
| S-EPMC6330086 | biostudies-literature
Unknown Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.
| S-EPMC4359958 | biostudies-literature